Cargando…

The red blood cell as a mediator of endothelial dysfunction in patients with familial hypercholesterolemia and dyslipidemia

BACKGROUND: Patients with familial hypercholesterolemia (FH) display high levels of low‐density lipoprotein cholesterol (LDL‐c), endothelial dysfunction, and increased risk of premature atherosclerosis. We have previously shown that red blood cells (RBCs) from patients with type 2 diabetes induce en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahdi, Ali, Wodaje, Tigist, Kövamees, Oskar, Tengbom, John, Zhao, Allan, Jiao, Tong, Henricsson, Marcus, Yang, Jiangning, Zhou, Zhichao, Nieminen, Anni I., Levin, Malin, Collado, Aida, Brinck, Jonas, Pernow, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092865/ https://www.ncbi.nlm.nih.gov/pubmed/36324273 http://dx.doi.org/10.1111/joim.13580

Ejemplares similares

Erythrocytes Induce Vascular Dysfunction in COVID-19
por: Mahdi, Ali, et al.
Publicado: (2022)

The Effect of Glycemic Control on Endothelial and Cardiac Dysfunction Induced by Red Blood Cells in Type 2 Diabetes
por: Mahdi, Ali, et al.
Publicado: (2019)

Erythrocytes from patients with ST-elevation myocardial infarction induce cardioprotection through the purinergic P2Y(13) receptor and nitric oxide signaling
por: Jiao, Tong, et al.
Publicado: (2022)

Red Blood Cell Peroxynitrite Causes Endothelial Dysfunction in Type 2 Diabetes Mellitus via Arginase
por: Mahdi, Ali, et al.
Publicado: (2020)

Stimulation of Erythrocyte Soluble Guanylyl Cyclase Induces cGMP Export and Cardioprotection in Type 2 Diabetes
por: Jiao, Tong, et al.
Publicado: (2023)

Erythrocytes induce vascular dysfunction in COVID-19
por: Mahdi, A, et al.
Publicado: (2021)

Red Blood Cells in Type 2 Diabetes Impair Cardiac Post-Ischemic Recovery Through an Arginase-Dependent Modulation of Nitric Oxide Synthase and Reactive Oxygen Species
por: Yang, Jiangning, et al.
Publicado: (2018)

Erythrocytes Induce Endothelial Injury in Type 2 Diabetes Through Alteration of Vascular Purinergic Signaling
por: Mahdi, Ali, et al.
Publicado: (2020)

Effect of Arginase Inhibition on Ischemia-Reperfusion Injury in Patients with Coronary Artery Disease with and without Diabetes Mellitus
por: Kövamees, Oskar, et al.
Publicado: (2014)

Hypoxic erythrocytes mediate cardioprotection through activation of soluble guanylate cyclase and release of cyclic GMP
por: Yang, Jiangning, et al.
Publicado: (2023)

Erythrocytes and cardiovascular complications
por: Zhou, Zhichao, et al.
Publicado: (2018)

The Draupadi of dyslipidemia: Familial hypercholesterolemia
por: Kalra, Sanjay, et al.
Publicado: (2016)

Altered Purinergic Receptor Sensitivity in Type 2 Diabetes-Associated Endothelial Dysfunction and Up(4)A-Mediated Vascular Contraction
por: Mahdi, Ali, et al.
Publicado: (2018)

Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
por: Sasaki, Jun
Publicado: (2010)

Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia
por: Fukami, Hirotaka, et al.
Publicado: (2021)

Prevalence of dyslipidemia and hypercholesterolemia awareness: results from the Lookup 7+ online project
por: Martone, Anna Maria, et al.
Publicado: (2022)

Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters
por: Vosper, Helen
Publicado: (2011)

Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands
por: Zuurbier, Linda C., et al.
Publicado: (2021)

The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies
por: Ferrara, Pietro, et al.
Publicado: (2021)

Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia
por: Surma, Stanisław, et al.
Publicado: (2023)

Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Viljoen, Adie, et al.
Publicado: (2010)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2009)

Mapping of familial hypercholesterolemia and dyslipidemias basic management infrastructure in Pakistan: a cross-sectional study
por: Sadiq, Fouzia, et al.
Publicado: (2023)

Severe Dyslipidemia Mimicking Familial Hypercholesterolemia Induced by High-Fat, Low-Carbohydrate Diets: A Critical Review
por: Houttu, Veera, et al.
Publicado: (2023)

Oral Unsaturated Fat Load Impairs Postprandial Systemic Inflammation in Primary Hypercholesterolemia Patients
por: Collado, Aida, et al.
Publicado: (2021)

Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members
por: Lin, Po-Chih, et al.
Publicado: (2022)

Prevalence and Patient Outcomes of Adult Primary Hypercholesterolemia and Dyslipidemia in the UK: Longitudinal Retrospective Study Using a Primary Care Dataset from 2009 to 2019
por: Bilitou, Aikaterini, et al.
Publicado: (2022)

Cardiovascular Outcomes in Patients With Both Diabetes and Phenotypic Familial Hypercholesterolemia: A Nationwide Register-Based Cohort Study
por: Brinck, Jonas, et al.
Publicado: (2022)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor
por: Jarauta, Estíbaliz, et al.
Publicado: (2020)

Optimal Use of Plant Stanol Ester in the Management of Hypercholesterolemia
por: Rosin, Susanna, et al.
Publicado: (2015)

Genetically confirmed familial hypercholesterolemia in outpatients with hypercholesterolemia
por: Wang, Xu, et al.
Publicado: (2018)

The Role of Arginase and Rho Kinase in Cardioprotection from Remote Ischemic Perconditioning in Non-Diabetic and Diabetic Rat In Vivo
por: Kiss, Attila, et al.
Publicado: (2014)

Differential DNA methylation in familial hypercholesterolemia
por: Reeskamp, Laurens F., et al.
Publicado: (2020)

Novel Immune Features of the Systemic Inflammation Associated with Primary Hypercholesterolemia: Changes in Cytokine/Chemokine Profile, Increased Platelet and Leukocyte Activation
por: Collado, Aida, et al.
Publicado: (2018)

Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review
por: Cicero, Arrigo F. G., et al.
Publicado: (2023)

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial
por: Tan, Hong, et al.
Publicado: (2023)

Familial Hypercholesterolemia
por: Baruah, Dibya Kumar
Publicado: (2021)

Prevalence of Dyslipidemia among School-Age Children and Adolescents in Addis Ababa, Ethiopia
por: Mohammed, Ousman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5att8ck8ppdauj35e0o4fmm6lu